The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

被引：40
|
作者：
Holubec, Lubos [1 ,4 ]
Polivka, Jiri, Jr. [1 ,2 ]
Safanda, Martin [4 ]
Karas, Michal [3 ]
Liska, Vaclav [1 ]
机构：
[1] Charles Univ Prague, Biomed Ctr, Fac Med Plzen, Plzen, Czech Republic
[2] Charles Univ Prague, Dept Histol & Embryol, Fac Med Plzen, Plzen, Czech Republic
[3] Charles Univ Prague, Dept Hematol & Oncol, Fac Med Plzen, Plzen, Czech Republic
[4] Na Homolce Hosp, Dept Clin Oncol, Prague, Czech Republic
来源：
ANTICANCER RESEARCH | 2016年 / 36卷 / 09期
关键词：
Colorectal cancer; cetuximab; immune response; targeted therapy; immunomodulation; review; GAMMA RECEPTOR POLYMORPHISMS; CHECKPOINT INHIBITORS; MONOCLONAL-ANTIBODIES; THERAPY; EGFR; IMMUNOTHERAPY; PANITUMUMAB; SURVIVAL; MICROENVIRONMENT; CYTOTOXICITY;
D O I：
10.21873/anticanres.10985
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.
引用
收藏
页码：4421 / 4426
页数：6
相关论文
共 50 条
  • [21] First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab
    Tonini, Giuseppe
    Calvieri, Alice
    Vincenzi, Bruno
    Santini, Daniele
    ONCOTARGETS AND THERAPY, 2009, 2 : 73 - 82
  • [22] TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
    Oden-Gangloff, A.
    Di Fiore, F.
    Bibeau, F.
    Lamy, A.
    Bougeard, G.
    Charbonnier, F.
    Blanchard, F.
    Tougeron, D.
    Ychou, M.
    Boissiere, F.
    Le Pessot, F.
    Sabourin, J-C
    Tuech, J-J
    Michel, P.
    Frebourg, T.
    BRITISH JOURNAL OF CANCER, 2009, 100 (08) : 1330 - 1335
  • [23] ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy in metastatic colorectal cancer
    Hong, Hi-Ju
    Shao, Yanfei
    Zhang, Sen
    Yang, Guang
    Jia, Hongtao
    Yang, Xiao
    Huang, Ling
    Li, Shuchun
    Aikemu, Batuer
    Zhang, Luyang
    Ma, Junjun
    Zang, Lu
    Sun, Jing
    Zheng, Minhua
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2022, 54 (11) : 1671 - 1683
  • [24] Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response
    Sud, S.
    O'Callaghan, C.
    Jonker, C.
    Karapetis, C.
    Price, T.
    Tebbutt, N.
    Shapiro, J.
    Van Hazel, G.
    Pavlakis, N.
    Gibbs, P.
    Jeffrey, M.
    Siu, L.
    Gill, S.
    Wong, R.
    Jonker, D.
    Tu, D.
    Goodwin, R.
    CURRENT ONCOLOGY, 2018, 25 (06) : E516 - E526
  • [25] Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis
    Neyns, B.
    Meert, V.
    Vandenbroucke, E.
    CURRENT ONCOLOGY, 2008, 15 (04) : 196 - 197
  • [26] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Miguel Jhonatan Sotelo
    Beatriz García-Paredes
    Carlos Aguado
    Javier Sastre
    Eduardo Díaz-Rubio
    World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
  • [27] The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
    Cui, Yuying
    Guo, Yingxue
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (04) : 843 - 851
  • [28] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Sotelo, Miguel Jhonatan
    Garcia-Paredes, Beatriz
    Aguado, Carlos
    Sastre, Javier
    Diaz-Rubio, Eduardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
  • [29] Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer
    Xynos, Ioannis D.
    Karadima, Maria L.
    Voutsas, Ioannis F.
    Amptoulach, Sousana
    Skopelitis, Elias
    Kosmas, Christos
    Gritzapis, Angelos D.
    Tsavaris, Nikolas
    ONCOLOGY, 2013, 84 (05) : 273 - 283
  • [30] Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab
    Jeeyun Lee
    Yong Sang Hong
    Jung Yong Hong
    Se Won Han
    Tae Won Kim
    Hye Jin Kang
    Tae You Kim
    Kyu-pyo Kim
    Suk Hyung Kim
    In-Gu Do
    Kyoung-Mee Kim
    Insuk Sohn
    Se Hoon Park
    Joon Oh Park
    Ho Yeong Lim
    Yong Beom Cho
    Woo Yong Lee
    Seong Hyeon Yun
    Hee Cheol Kim
    Young Suk Park
    Won Ki Kang
    Investigational New Drugs, 2014, 32 : 535 - 541
12345